CD274 and cancer: Immune checkpoint inhibitors (ICIs), particularly inhibitors of cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death receptor-1 (PD-1) and its associated ligand (PD-L1), represent an important development in the treatment of advanced cancers (Champiat et al, 2016).